DOD Pancreatic Cancer, Focused Pilot Award
ID: 353861Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353861
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Pancreatic Cancer Research Program (PCARP) Focused Pilot Award to support innovative research aimed at improving treatment and quality of life for individuals affected by pancreatic cancer. This grant encourages projects that explore patient-centered research areas, such as healthcare access, mental health correlations, and supportive care interventions, with a focus on generating robust preliminary data for future studies. The total funding available for this program is $1.28 million, with grants capped at $200,000 over a two-year performance period. Key deadlines include a pre-application submission by September 18, 2024, and a full application by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524PCARPFPTA_GG.pdf
    The Department of Defense (DOD) is announcing the FY24 Pancreatic Cancer Research Program (PCARP) Focused Pilot Award, aimed at supporting innovative research that significantly impacts pancreatic cancer treatment and quality of life for affected individuals. With a total funding allocation of $15 million, this program encourages projects that explore supportive care interventions, identify healthcare implementation barriers, and address patient-reported outcomes. Key submission deadlines include a pre-application by September 18, 2024, and a full application by October 3, 2024. Eligible applicants range from academic institutions to for-profit organizations, with grants capped at $200,000 across a two-year performance period. The application process involves both a pre-application submission through eBRAP and a full application via Grants.gov, with all components adhering to specific formatting and content guidelines. Evaluation criteria consist of scientific merit, innovation in research methodologies, and the potential impact on improving patient outcomes. Applications undergo a two-tier review process, first assessing technical merit and then program relevance. Successful applicants will receive funding notifications by September 30, 2025. This opportunity emphasizes collaboration, encourages exploration of under-researched health issues, and aims to foster advancements in the battle against pancreatic cancer.
    Similar Opportunities
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Research Projects aimed at combating Antibiotic-Resistant Bacteria (CARB). This initiative invites applications for grant funding to enhance appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections across various healthcare settings. With a focus on addressing significant public health threats posed by antibiotic resistance, the grants can fund projects up to $2.5 million over five years, with annual budgets not exceeding $500,000. Interested applicants must adhere to detailed submission guidelines, and the application deadline is October 30, 2026. For further inquiries, applicants can contact AHRQ at GrantQueries@ahrq.hhs.gov.
    Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)
    Agency for Health Care Research and Quality
    The Agency for Healthcare Research and Quality (AHRQ) is offering a funding opportunity for Large Health Services Research Demonstration and Dissemination Projects aimed at combating Antibiotic-Resistant Bacteria (CARB) under the R18 grant mechanism. The initiative seeks to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent healthcare-associated infections, addressing significant public health concerns with over 2.8 million infections occurring annually in the U.S. Eligible applicants include educational institutions, non-profits, state and local governments, and various organizations focused on healthcare improvements, with funding available up to $500,000 per year for a maximum of five years, totaling no more than $2.5 million. Interested parties should submit their applications by October 30, 2026, and can direct inquiries to GrantQueries@ahrq.hhs.gov for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Staff Research Program
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity for the Staff Research Program, aimed at engaging scientific staff in collaborative research with higher education institutions. This program seeks to enhance the professional competence of Army Research Office (ARO) scientists through hands-on, fundamental research in various scientific fields, including engineering, physical sciences, and life sciences, with a focus on advancing knowledge relevant to Army missions. Eligible applicants include institutions recognized for their scientific research capabilities, and the funding will be provided through cooperative agreements with award amounts ranging from $200,000 to $10 million. Proposals must be submitted via Grants.gov by June 2, 2030, and interested parties can contact Mr. William Creech at William.a.creech3.civ@army.mil for further information.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.